FDA approves GSK's Advil Dual Action with Acetaminophen for over-the-counter use in the United States
Advil Dual Action is an exclusive pain-fighting formula, combining ibuprofen and acetaminophen to fight pain in two ways. Ibuprofen is a nonsteroidal anti-inflammatory (NSAID) that targets pain at the source, temporarily reducing the production of prostaglandins, which cause swelling and pain signals. Acetaminophen is a pain reliever that blocks the transmission of pain signals to the brain. Advil Dual Action will be available over-the-counter nationwide in 2020. GSK's commitment to pain relief
We are the world leader in pain relief. With a portfolio of (systemic and topical) products to relieve pain, our range brings comfort and ease to millions. World-leading brands including Advil, Panadol and Voltaren; and beloved local brands like Excedrin in the US and Fenbid in?China?help people manage their symptoms so they can enjoy life to the fullest. Important safety information about Advil Dual Action
Before using the product, consumers should read the Advil Dual Action drug facts label. About GSK
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit?www.gsk.com. About GSK Consumer Healthcare
We are the world's largest Consumer Healthcare company following our new joint venture with Pfizer Consumer Healthcare. The new drug application for Advil Dual Action was approved under the Pfizer name. We develop and market a portfolio of consumer-preferred and expert-recommended brands including Sensodyne, parodontax, Poligrip, Advil, Centrum and Theraflu.
GSK enquiries: |
|||
UK Media enquiries: |
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
Eleanor Bunch |
+44 (0) 20 8047 5502 |
(London) |
|
US Media enquiries: |
Caitlin Kormann |
+1 617 448 0557 |
(Warren) |
Analyst/Investor enquiries: |
Sarah Elton-Farr |
+44 (0) 208 047 5194 |
(London) |
Danielle Smith |
+44 (0) 20 8047 7562 |
(London) |
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018. |
|
Registered in England & Wales: No. 3888792 |
|
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS |